135 related articles for article (PubMed ID: 30745708)
1. Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.
Tighiouart M
J R Stat Soc Ser C Appl Stat; 2019 Jan; 68(1):235-250. PubMed ID: 30745708
[TBL] [Abstract][Full Text] [Related]
2. Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials.
Jiménez JL; Tighiouart M
J R Stat Soc Ser C Appl Stat; 2022 Nov; 71(5):1996-2013. PubMed ID: 36779084
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations.
Jiménez JL; Kim S; Tighiouart M
Biom J; 2020 Sep; 62(5):1300-1314. PubMed ID: 32150296
[TBL] [Abstract][Full Text] [Related]
4. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
Tighiouart M; Piantadosi S; Rogatko A
Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials.
Tighiouart M; Li Q; Piantadosi S; Rogatko A
Am J Biostat; 2016; 6(1):1-11. PubMed ID: 28706582
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
Tighiouart M; Li Q; Rogatko A
Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.
Diniz MA; Kim S; Tighiouart M
J Probab Stat; 2018; 2018():. PubMed ID: 30906326
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.
Diniz MA; Kim S; Tighiouart M
Stats (Basel); 2020 Sep; 3(3):221-238. PubMed ID: 33073179
[TBL] [Abstract][Full Text] [Related]
9. Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
Tighiouart M; Jiménez JL; Diniz MA; Rogatko A
Braz J Biom; 2022 Dec; 40(4):453-468. PubMed ID: 38357386
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
Tighiouart M; Cook-Wiens G; Rogatko A
J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
[TBL] [Abstract][Full Text] [Related]
11. Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.
Diniz MA; Quanlin-Li ; Tighiouart M
J Biom Biostat; 2017; 8(6):. PubMed ID: 29552377
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
[TBL] [Abstract][Full Text] [Related]
13. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Chen Z; Tighiouart M; Kowalski J
Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
[TBL] [Abstract][Full Text] [Related]
15. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials.
Zhang L; Yuan Y
Stat Med; 2016 Nov; 35(27):4924-4936. PubMed ID: 27580928
[TBL] [Abstract][Full Text] [Related]
16. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
Yada S; Hamada C
Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
[TBL] [Abstract][Full Text] [Related]
17. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
18. Escalation strategies for combination therapy Phase I trials.
Sweeting MJ; Mander AP
Pharm Stat; 2012; 11(3):258-66. PubMed ID: 22411472
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs.
Dejardin D; Lesaffre E; Hamberg P; Verweij J
Pharm Stat; 2014; 13(3):196-207. PubMed ID: 24715683
[TBL] [Abstract][Full Text] [Related]
20. A software tool for both the maximum tolerated dose and the optimal biological dose finding trials in early phase designs.
Li C; Sun H; Cheng C; Tang L; Pan H
Contemp Clin Trials Commun; 2022 Dec; 30():100990. PubMed ID: 36203850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
